Lakefront Biotherapeutics NV (LKFT) financial statements
Lakefront Biotherapeutics NV reported revenue of 1.1B EUR in fiscal 2025, up 27.0% a year over 9 years.
Net income was 321M EUR and the operating margin 26.5%, against -8.9% in 2016.
Free cash flow was -271M EUR.
The diluted share count rose 39% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions (EUR).
Income statement
Fiscal years, in EUR, from Lakefront Biotherapeutics NV's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 130M EUR | 127M EUR | 279M EUR | 835M EUR | 478M EUR | 234M EUR | 241M EUR | 240M EUR | 276M EUR | 1.1B EUR |
| Cost of revenue | — | — | — | — | — | 2M EUR | 12M EUR | — | 35M EUR | 30M EUR |
| Gross profit | — | — | — | — | — | 233M EUR | 229M EUR | — | 241M EUR | 1.1B EUR |
| Research and development | 140M EUR | 219M EUR | 316M EUR | 420M EUR | 524M EUR | 321M EUR | 270M EUR | 241M EUR | 335M EUR | 459M EUR |
| Selling, general and admin | 22M EUR | 24M EUR | 34M EUR | 72M EUR | 119M EUR | 128M EUR | 135M EUR | 128M EUR | 117M EUR | 147M EUR |
| Operating income | -11M EUR | -90M EUR | -47M EUR | 369M EUR | -179M EUR | -172M EUR | -131M EUR | -88M EUR | -188M EUR | 295M EUR |
| Interest expense | 47,000 EUR | 936,000 EUR | 780,000 EUR | 1M EUR | 9M EUR | 12M EUR | 7M EUR | 2M EUR | 911,000 EUR | 1M EUR |
| Pre-tax income | 54M EUR | -116M EUR | -31M EUR | 149M EUR | -310M EUR | -119M EUR | -71M EUR | 6M EUR | -3M EUR | 301M EUR |
| Income tax | 235,000 EUR | 198,000 EUR | 822,000 EUR | -165,000 EUR | 1M EUR | 1M EUR | 572,000 EUR | 10M EUR | -2M EUR | -19M EUR |
| Net income | 54M EUR | -116M EUR | -29M EUR | 150M EUR | -305M EUR | -103M EUR | -218M EUR | 212M EUR | 74M EUR | 321M EUR |
| EPS (diluted) | 1.14 EUR | -2.34 EUR | -0.56 EUR | 2.49 EUR | -4.69 EUR | -1.58 EUR | -3.32 EUR | 3.21 EUR | 1.12 EUR | 4.87 EUR |
| Diluted shares | 47M | 49M | 52M | 58M | 65M | 66M | 66M | 66M | 66M | 66M |
| Gross margin | — | — | — | — | — | 99.3% | 95.0% | — | 87.4% | 97.3% |
| Operating margin | -8.9% | -70.7% | -16.9% | 44.2% | -37.4% | -73.2% | -54.3% | -36.8% | -68.3% | 26.5% |
| Net margin | 41.7% | -91.0% | -10.5% | 17.9% | -63.9% | -44.0% | -90.4% | 88.3% | 26.9% | 28.9% |
Balance sheet
Fiscal years, in EUR, from Lakefront Biotherapeutics NV's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | 973M EUR | 1.2B EUR | 1.3B EUR | 5.8B EUR | 5.2B EUR | 4.7B EUR | 4.1B EUR | 3.7B EUR | 3.1B EUR | 3.0B EUR |
| Receivables | 10M EUR | 28M EUR | 19M EUR | 54M EUR | 148M EUR | 111M EUR | 40M EUR | 28M EUR | 47M EUR | 21M EUR |
| Inventory | 300,000 EUR | 279,000 EUR | 276,000 EUR | 255,000 EUR | 36,000 EUR | 21M EUR | 53M EUR | 74M EUR | 51M EUR | 22M EUR |
| Total current assets | 1.0B EUR | 1.2B EUR | 1.3B EUR | 5.9B EUR | 5.4B EUR | 4.9B EUR | 4.2B EUR | 3.9B EUR | 3.3B EUR | 3.1B EUR |
| Property, plant and equipment | 15M EUR | 17M EUR | 23M EUR | 41M EUR | 68M EUR | 106M EUR | 127M EUR | 111M EUR | 105M EUR | 72M EUR |
| Goodwill | — | — | — | — | — | — | 70M EUR | 70M EUR | 70M EUR | — |
| Total assets | 1.1B EUR | 1.3B EUR | 1.4B EUR | 6.1B EUR | 5.7B EUR | 5.2B EUR | 4.7B EUR | 4.4B EUR | 4.1B EUR | 3.4B EUR |
| Total current liabilities | 104M EUR | 172M EUR | 220M EUR | 572M EUR | 635M EUR | 566M EUR | 523M EUR | 428M EUR | 335M EUR | 153M EUR |
| Total liabilities | 325M EUR | 274M EUR | 225M EUR | 3.2B EUR | 3.0B EUR | 2.5B EUR | 2.2B EUR | 1.6B EUR | 1.2B EUR | 171M EUR |
| Shareholders' equity | 759M EUR | 1.0B EUR | 1.2B EUR | 2.9B EUR | 2.7B EUR | 2.6B EUR | 2.5B EUR | 2.8B EUR | 2.9B EUR | 3.2B EUR |
| Net debt | -973M EUR | -1.2B EUR | -1.3B EUR | -1.9B EUR | -2.1B EUR | -2.2B EUR | -508M EUR | -167M EUR | -64M EUR | -88M EUR |
Cash flow
Fiscal years, in EUR, from Lakefront Biotherapeutics NV's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 239M EUR | -147M EUR | -142M EUR | 3.2B EUR | -427M EUR | -504M EUR | -501M EUR | -406M EUR | -320M EUR | -257M EUR |
| Capital spending | 5M EUR | 7M EUR | 14M EUR | 46M EUR | 91M EUR | 58M EUR | 37M EUR | 19M EUR | 82M EUR | 14M EUR |
| Free cash flow | 235M EUR | -154M EUR | -156M EUR | 3.2B EUR | -519M EUR | -562M EUR | -537M EUR | -425M EUR | -402M EUR | -271M EUR |
| Stock-based compensation | 11M EUR | 17M EUR | 27M EUR | 38M EUR | 80M EUR | 71M EUR | 89M EUR | 57M EUR | 20M EUR | 24M EUR |
| Free cash flow margin | 181.1% | -121.5% | -56.0% | 378.8% | -108.5% | -239.7% | -222.8% | -177.4% | -145.9% | -24.4% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for LKFT.
Open LKFT in InvestinglyQuestions
What was Lakefront Biotherapeutics NV's revenue in 2025?
1.1B EUR in fiscal 2025, from its 10-K filing.
How much free cash flow does Lakefront Biotherapeutics NV generate?
-271M EUR in fiscal 2025 (operating cash flow minus capital spending).
From Lakefront Biotherapeutics NV's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.